Antibody-mediated protection against respiratory viral infection

Seminars in Respiratory and Critical Care Medicine

Volumn 26, Issue 6, 2005, Pages 635-642

  Dubois, Melissa E ^a   Yoshihara, Paul ^b   Slifka, Mark K ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Najít Technologies Inc   (United States)

Author keywords

Antibody mediated therapy; Host defenses; Monoclonal antibody; Respiratory; Respiratory virus; Vaccine; Virus

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PALIVIZUMAB; POLYCLONAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANTIBODY RESPONSE; DISEASE EXACERBATION; HUMAN; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; IMMUNOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYSTEM; REVIEW; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; HUMANS; RESPIRATORY TRACT INFECTIONS; VACCINATION; VIRAL VACCINES; VIRUS DISEASES;

EID: 30344466946     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-925527     Document Type: Review

References (57)

1. Whitton JL, Slifka MK, Liu F, et al. The regulation and maturation of antiviral immune responses. Adv Virus Res 2004;63:181-238
2. Slifka MK, Hanifin JM. Smallpox: the basics. Dermatol Clin 2004;22:263-274 vi
3. Epstein SL, Lo CY, Misplon JA, et al. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. J Immunol 1997;158:1222-1230
4. Edghill-Smith Y, Bray M, Whitehouse CA, et al. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J Infect Dis 2005;191:372-381
5. Bouvet JP, Fischetti VA. Diversity of antibody-mediated immunity at the mucosal barrier. Infect Immun 1999;67: 2687-2691
6. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11(Suppl 4):77-95
7. Slifka MK, Ahmed R. Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity. Trends Microbiol 1996;4:394-400
8. Franklin EC. Structure and function of immunoglobulins. Acta Endocrinol Suppl (Copenh) 1975;194:77-95
9. Stockwin LH, Holmes S. Antibodies as therapeutic agents: vive la renaissance!. Expert Opin Biol Ther 2003;3:1133-1152
10. Burton DR. Opinion: antibodies, viruses and vaccines. Nat Rev Immunol 2002;2:706-713
11. Griffin D, Levine B, Tyor W, et al. The role of antibody in recovery from alphavirus encephalitis. Immunol Rev 1997; 159:155-161
12. Fujioka H, Emancipator SN, Aikawa M, et al. Immunocytochemical colocalization of specific immunoglobulin A with Sendai virus protein in infected polarized epithelium. J Exp Med 1998;188:1223-1229
13. Mazanec MB, Coudret CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 1995;69: 1339-1343
14. Bomsel M, Heyman M, Hocini H, et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998;9:277-287
15. Kato H, Kato R, Fujihashi K, McGhee JR. Role of mucosal antibodies in viral infections. Curr Top Microbiol Immunol 2001;260:201-228
16. Schmaljohn AL, Johnson ED, Dalrymple JM, Cole GA. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature 1982;297:70-72
17. Gould EA, Buckley A, Barrett AD, Cammack N. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol 1986; 67(Pt 3):591-595
18. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies: comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004;59:1-15
19. Tamura S, Iwasaki T, Thompson AH, et al. Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection. J Gen Virol 1998;79(Pt 2): 291-299
20. Tamura S, Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 2004;57:236-247
21. Renegar KB, Small PA Jr, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004;173:1978-1986
22. Fenner F, Henderson DA, Arita I, et al. Smallpox and Its Eradication: The Pathogenesis, Immunology, and Pathology of Smallpox and Vaccinia. Geneva: World Health Organization; 1988
23. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9:1131-1137
24. Crotty S, Feigner P, Davies H, et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003;171:4969-4973
25. CDC. Impact of vaccines universally recommended for children: United States, 1990-1998. MMWR Morb Mortal Wkly Rep 1999;48:243-248
26. Amanna I, Slifka MK. Public fear of vaccination: separating fact from fiction. Viral Immunol 2005;18:307-315
27. Christie CD, Marx ML, Daniels JA, Adcock MP. Pertussis containment in schools and day care centers during the Cincinnati epidemic of 1993. Am J Public Health 1997;87: 460-462
28. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89: 422-434
29. Chin J, Magoffin RL, Shearer LA, et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969; 89:449-463
30. Fulginiti VA, Eller JJ, Sieber OF, et al. Respiratory virus immunization, I: A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969;89:435-448
31. Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-421
32. Chihrin S, Loutfy MR. Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome. Expert Rev Anti Infect Ther 2005;3:251-262
33. Wesselhoeft C. Treatment of scarlet fever and diphtheria. Med Clin North Am 1936;19:1389-1407
34. Skerrett SJ. Antibody treatment of lower respiratory tract infections. Semin Respir Infect 2001;16:67-75
35. Zeitlin L, Cone RA, Moench TR, Whaley KJ. Preventing infectious disease with passive immunization. Microbes Infect 2000;2:701-708
36. Casadevall A. Passive antibody therapies: progress and continuing challenges. Clin Immunol 1999;93:5-15
37. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis 1996;2:200-208
38. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995;21:150-161
39. Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antiviral Res 2000;47:57-77
40. Dunman PM, Nesin M. Passive immunization as prophylaxis: when and where will this work? Curr Opin Pharmacol 2003;3: 486-496
41. Liu W, Zou P, Chen YH. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 2004;93:131-136
42. Traggiai E, Becker S, Subbarao K, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004; 10:871-875
43. Maggon K, Barik S. New drugs and treatment for respiratory syncytial virus. Rev Med Virol 2004;14:149-168
44. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005;36:3-10
45. Peterson NC. Advances in monoclonal antibody technology: genetic engineering of mice, cells, and immunoglobulins. ILAR J 2005;46:314-319
46. American Academy of Pediatrics. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112(6 Pt 1): 1442-1446
47. DeVincenzo JP, Hall CB, Kimberlin DW, et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis 2004;190:975-978
48. Zhao X, Chen FP, Sullender WM. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 2004;318:608-612
49. Zhao X, Chen FP, Megaw AG, Sullender WM. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis 2004;190:1941-1946
50. Yang ZY, Werner HC, Kong WP, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci U S A 2005;102:797-801
51. Lang AB, Cryz SJ Jr, Schurch U, et al. Immunotherapy with human monoclonal antibodies: fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J Immunol 1993;151: 466-472
52. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005;24:44-46
53. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000; 13:602-614
54. Harrison LH, Halsey NA, McKee KT Jr, et al. Clinical case definitions for Argentine hemorrhagic fever. Clin Infect Dis 1999;28:1091-1094
55. Enria DA, Barrera Oro JG. Junin virus vaccines. Curr Top Microbiol Immunol 2002;263:239-261
56. Patel TB, Naidu BPB. Smallpox and sulphonamide. Indian Med Gaz 1940;75:730-732
57. Couzi G, Kircher JP. Immunotherapie de la Variole. Bulletin de l'Institut d'hygiene du Maroc 1941;1:59-68